clinical trial · NCT05557942
Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial - Follow Up Long Term Extension (IMPAHCT-FUL)
Aerovate Therapeutics·phase3·terminated·n = 186
Pulmonary Arterial HypertensionAV-101
brief summary
IMPAHCT-FUL: Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial - Follow Up Long Term Extension (LTE) Trial was a follow up study to establish the long-term safety of AV-101. Subjects who successfully completed the 24-week placebo-controlled parent trial (AV-101-002, NCT#05036135) were offered the opportunity to continue into this LTE study. Subjects who enrolled in the study were to receive one of three active AV-101 doses until such time as the optimal dose was selected in the parent study.
started
Nov 2, 2022
primary completion
Aug 8, 2024
completion
Aug 8, 2024
last updated
Oct 10, 2024
official title
A Long-Term Extension, Multi-Center Safety Study of AV-101 in Subjects With Pulmonary Arterial Hypertension (PAH) Who Have Completed Study AV-101-002 (IMPAHCT-FUL)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol